对《晚期前列腺癌初治患者使用Ac-PSMA-617的初步研究》的勘误
Correction to: Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study.
作者信息
Sathekge Mike, Bruchertseifer Frank, Knoesen Otto, Reyneke Florette, Lawal Ismaheel, Lengana Thabo, Davis Cindy, Mahapane Johncy, Corbett Ceceila, Vorster Mariza, Morgenstern Alfred
机构信息
Department of Nuclear Medicine, Steve Biko Academic Hospital, University of Pretoria, Private Bag X169, Pretoria, 0001, South Africa.
European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe, Germany.
出版信息
Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):1988. doi: 10.1007/s00259-019-04401-9.
Abstract
The author of this article wanted to change the ethical approval statement of the originally published version of this article. Correct statement is indicated below.
摘要
本文作者希望更改本文最初发表版本的伦理批准声明。正确声明如下所示。
相似文献
1
Correction to: Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study.对《晚期前列腺癌初治患者使用Ac-PSMA-617的初步研究》的勘误
Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):1988. doi: 10.1007/s00259-019-04401-9.
2
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding.转移性去势抵抗性前列腺癌的靶向 α 治疗：Ac-PSMA-617 的剂量估算和经验剂量探索。
J Nucl Med. 2017 Oct;58(10):1624-1631. doi: 10.2967/jnumed.117.191395. Epub 2017 Apr 13.
3
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
4
225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.225Ac-PSMA-617用于转移性去势抵抗性前列腺癌的PSMA靶向α放射治疗。
J Nucl Med. 2016 Dec;57(12):1941-1944. doi: 10.2967/jnumed.116.178673. Epub 2016 Jul 7.
5
Author Correction: The CLE9/10 secretory peptide regulates stomatal and vascular development through distinct receptors.
Nat Plants. 2019 Feb;5(2):238. doi: 10.1038/s41477-018-0347-y.
6
Results of a Prospective Phase 2 Pilot Trial of Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression.Lu-PSMA-617 治疗转移性去势抵抗性前列腺癌的前瞻性 2 期试验结果，包括治疗反应的影像学预测因子和进展模式。
Clin Genitourin Cancer. 2019 Feb;17(1):15-22. doi: 10.1016/j.clgc.2018.09.014. Epub 2018 Sep 27.
7
Preliminary results on response assessment using Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy.使用 Ga-HBED-CC-PSMA PET/CT 评估转移性前列腺癌患者接受多西他赛化疗后反应的初步结果。
Eur J Nucl Med Mol Imaging. 2018 Apr;45(4):602-612. doi: 10.1007/s00259-017-3887-x. Epub 2017 Nov 28.
8
Author Correction: Inflammasome signalling in brain function and neurodegenerative disease.作者更正：炎症小体信号在脑功能和神经退行性疾病中的作用
Nat Rev Neurosci. 2019 Mar;20(3):187. doi: 10.1038/s41583-019-0137-1.
9
Intraindividual Comparison of F-PSMA-1007 and F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study.个体内比较 F-PSMA-1007 和 F-DCFPyL PET/CT 在新诊断前列腺癌患者中的前瞻性评估：一项初步研究。
J Nucl Med. 2018 Jul;59(7):1076-1080. doi: 10.2967/jnumed.117.204669. Epub 2017 Dec 21.
10
Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of Ga, In, Lu and Ac.评估携带新型螯合物的PSMA靶向配体在诊疗学中的应用：镓、铟、镥和锕的稳定性及络合动力学
Nucl Med Biol. 2017 Dec;55:38-46. doi: 10.1016/j.nucmedbio.2017.10.001. Epub 2017 Oct 3.
引用本文的文献
1
Alpha Particle-Emitting Radiopharmaceuticals as Cancer Therapy: Biological Basis, Current Status, and Future Outlook for Therapeutics Discovery.《用于癌症治疗的α粒子发射放射性药物：治疗学发现的生物学基础、现状和未来展望》
Mol Imaging Biol. 2023 Dec;25(6):991-1019. doi: 10.1007/s11307-023-01857-y. Epub 2023 Oct 16.
2
Actinium-225 Targeted Agents: Where Are We Now?锕-225 靶向药物：我们现在在哪里？
Brachytherapy. 2023 Nov-Dec;22(6):697-708. doi: 10.1016/j.brachy.2023.06.228. Epub 2023 Sep 9.
3
Competitive blocking of salivary gland [F]DCFPyL uptake via localized, retrograde ductal injection of non-radioactive DCFPyL: a preclinical study.通过局部逆行导管注射非放射性DCFPyL竞争性阻断唾液腺[F]DCFPyL摄取：一项临床前研究。
EJNMMI Res. 2021 Jul 21;11(1):66. doi: 10.1186/s13550-021-00803-9.
4
Evaluation of Actinium-225 Labeled Minigastrin Analogue [Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy.用于靶向α粒子治疗的锕-225标记的迷你胃泌素类似物[Ac]Ac-DOTA-PP-F11N的评估
Pharmaceutics. 2020 Nov 12;12(11):1088. doi: 10.3390/pharmaceutics12111088.
5
Current status of radioligand therapy and positron-emission tomography with prostate-specific membrane antigen.前列腺特异性膜抗原放射性配体治疗与正电子发射断层扫描的现状。
Ann Nucl Med. 2020 Dec;34(12):879-883. doi: 10.1007/s12149-020-01549-5. Epub 2020 Nov 11.
Zotero 插件